{"id":"moxifloxacin-avelox","safety":{"commonSideEffects":[{"rate":"3-7%","effect":"Nausea"},{"rate":"5-7%","effect":"Diarrhea"},{"rate":"1-3%","effect":"Dizziness"},{"rate":"<1%","effect":"Tendinitis/tendon rupture"},{"rate":"<1%","effect":"QT prolongation"},{"rate":"<1%","effect":"Photosensitivity"},{"rate":"<1%","effect":"Peripheral neuropathy"}]},"_chembl":{"chemblId":"CHEMBL32","moleculeType":"Small molecule","molecularWeight":"401.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a fluoroquinolone antibiotic, moxifloxacin binds to and inhibits DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for bacterial DNA replication and repair. This dual inhibition leads to rapid bactericidal activity against a broad spectrum of aerobic and anaerobic bacteria. The drug is particularly effective against respiratory pathogens and has enhanced activity against gram-positive organisms compared to earlier fluoroquinolones.","oneSentence":"Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:34:41.645Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Community-acquired bacterial pneumonia"},{"name":"Acute bacterial sinusitis"},{"name":"Acute bacterial exacerbation of chronic bronchitis"},{"name":"Uncomplicated skin and soft tissue infections"},{"name":"Complicated skin and soft tissue infections"},{"name":"Intra-abdominal infections"}]},"trialDetails":[{"nctId":"NCT06253715","phase":"PHASE3","title":"Shortened Regimen for Drug-susceptible TB in Children","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-01-15","conditions":"Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Lymph Node","enrollment":860},{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":300},{"nctId":"NCT07422298","phase":"PHASE1","title":"A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-02-19","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT06200467","phase":"PHASE1","title":"A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2024-03-13","conditions":"Overweight, Obesity","enrollment":110},{"nctId":"NCT07305831","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-22","conditions":"Healthy","enrollment":62},{"nctId":"NCT07074327","phase":"PHASE1","title":"Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-07-11","conditions":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","enrollment":74},{"nctId":"NCT07116915","phase":"PHASE1","title":"A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD.","status":"RECRUITING","sponsor":"Guangdong Hengrui Pharmaceutical Co., Ltd","startDate":"2025-08-11","conditions":"COPD","enrollment":160},{"nctId":"NCT05398679","phase":"PHASE4","title":"Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":"Endocarditis Infective","enrollment":360},{"nctId":"NCT07225699","phase":"NA","title":"IN PATIENTS WITH CORNEAL ABRASIONS TREATED WITH COLLAGEN CORNEAL SHIELDS IN THE EMERGENCY DEPARTMENT SETTING","status":"NOT_YET_RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2026-05-15","conditions":"Corneal Abrasions","enrollment":60},{"nctId":"NCT01416259","phase":"","title":"A Phase I Study of the Effects of APF530 Exposure, Granisetron and Moxifloxacin","status":"COMPLETED","sponsor":"Heron Therapeutics","startDate":"2011-07","conditions":"Healthy","enrollment":56},{"nctId":"NCT06153069","phase":"PHASE4","title":"Asymptomatic TB With Innovative Modified Short-course Regimens","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-11-21","conditions":"Tuberculosis","enrollment":426},{"nctId":"NCT06537609","phase":"NA","title":"A Platform Trial for Gram Negative Bloodstream Infections","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2024-04-24","conditions":"Gram-negative Bacteremia","enrollment":2500},{"nctId":"NCT07209761","phase":"PHASE3","title":"A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2025-10-16","conditions":"Pulmonary Tuberculosis","enrollment":532},{"nctId":"NCT07394257","phase":"NA","title":"Intrastromal Moxifloxacin as an Adjunctive Therapy in Recalcitrant Bacterial Keratitis","status":"RECRUITING","sponsor":"Minia University","startDate":"2025-10-01","conditions":"Bacterial Keratitis, Recalcitrant Infectious Keratitis, Corneal Ulcer","enrollment":60},{"nctId":"NCT07308938","phase":"PHASE2","title":"Fluorometholone Study","status":"NOT_YET_RECRUITING","sponsor":"Vishal Jhanji","startDate":"2026-03-31","conditions":"Keratitis Bacterial, Corneal Ulcer (Diagnosis)","enrollment":174},{"nctId":"NCT07378579","phase":"PHASE1","title":"An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001","status":"COMPLETED","sponsor":"Alumis Inc","startDate":"2024-06-21","conditions":"Healthy Volunteer","enrollment":52},{"nctId":"NCT07170800","phase":"PHASE2","title":"A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets","status":"RECRUITING","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2025-09-19","conditions":"Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis","enrollment":60},{"nctId":"NCT05110001","phase":"PHASE3","title":"Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2022-08-03","conditions":"Acanthamoeba Keratitis, Fungal Keratitis","enrollment":330},{"nctId":"NCT07063238","phase":"PHASE1","title":"A Clinical Study of MK-8527 in Healthy Adult Participants (MK-8527-014)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-08-12","conditions":"Healthy","enrollment":42},{"nctId":"NCT07229157","phase":"PHASE1","title":"Effect of Maridebart Cafraglutide on the Heart's Electrical Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2025-10-22","conditions":"Overweight, Obesity","enrollment":81},{"nctId":"NCT06441006","phase":"PHASE2, PHASE3","title":"Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-10-03","conditions":"Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR","enrollment":400},{"nctId":"NCT06795204","phase":"PHASE1","title":"Effects of HSK3486 on Cardiac Repolarization in Health Subjects (TQT)","status":"COMPLETED","sponsor":"Haisco-USA Pharmaceuticals, Inc.","startDate":"2024-04-09","conditions":"Anesthesia; Adverse Effect, Cardiac Arrhythmia","enrollment":48},{"nctId":"NCT07272629","phase":"PHASE1","title":"A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-12-04","conditions":"Cardiac Repolarization, Healthy Volunteers","enrollment":44},{"nctId":"NCT03481881","phase":"","title":"Pharmacokinetics of Drugs Administered to Children","status":"RECRUITING","sponsor":"Duke University","startDate":"2013-08-14","conditions":"Pediatric ALL","enrollment":200},{"nctId":"NCT07023029","phase":"PHASE1","title":"A Study on the Effect of Etavopivat on Heart Rhythm in Healthy Participants","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2025-06-09","conditions":"Healthy Volunteers, Sickle Cell Disease, Thalassemia","enrollment":33},{"nctId":"NCT07305987","phase":"PHASE3","title":"PRO-232 in Patients Subjected to Cataract Surgery","status":"RECRUITING","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2025-10-27","conditions":"Cataract Extraction","enrollment":134},{"nctId":"NCT06271772","phase":"PHASE3","title":"Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction II","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-07-01","conditions":"Bacterial Keratitis","enrollment":60},{"nctId":"NCT04722978","phase":"PHASE3","title":"Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen University Cancer Center","startDate":"2021-04-20","conditions":"Triple Negative Breast Cancer","enrollment":228},{"nctId":"NCT05114720","phase":"PHASE3","title":"Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2021-11-11","conditions":"Breast Cancer","enrollment":559},{"nctId":"NCT06294600","phase":"PHASE3","title":"Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)","status":"RECRUITING","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2024-02-12","conditions":"Community-acquired Pneumonia","enrollment":330},{"nctId":"NCT07276802","phase":"PHASE4","title":"The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery)","status":"NOT_YET_RECRUITING","sponsor":"Research Insight LLC","startDate":"2025-12-05","conditions":"Post Cataract Surgery","enrollment":40},{"nctId":"NCT07274020","phase":"PHASE3","title":"Long-Term Safety and Efficacy of Moxifloxacin in Bronchiectasis Patients","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-12-01","conditions":"Bronchiectasis, Non-Cystic Fibrosis","enrollment":140},{"nctId":"NCT05630872","phase":"PHASE2","title":"Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-02-13","conditions":"HIV-associated Tuberculosis","enrollment":30},{"nctId":"NCT07268664","phase":"PHASE3","title":"Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort","status":"NOT_YET_RECRUITING","sponsor":"Beijing Chest Hospital","startDate":"2025-12-01","conditions":"Rifampicin Resistant Tuberculosis, Pulmonary Tuberculosis, Tuberculosis","enrollment":120},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT06905522","phase":"PHASE3","title":"A PAN-USR TB Multi-Center Trial","status":"RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-06-18","conditions":"Pulmonary Tuberculosis","enrollment":610},{"nctId":"NCT06107036","phase":"PHASE1","title":"A Study in Healthy People to Test Whether Different Doses of BI 1015550 Have Potential to Induce Heart Rhythm Abnormalities","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2024-03-06","conditions":"Healthy","enrollment":46},{"nctId":"NCT07212803","phase":"PHASE4","title":"Effects of Energy Drinks on Cardiovascular Endpoints","status":"RECRUITING","sponsor":"University of the Pacific","startDate":"2025-11-01","conditions":"Healthy Volunteers, Safety After Oral Intake","enrollment":3},{"nctId":"NCT01298336","phase":"PHASE3","title":"Treatment of Mycobacterium Xenopi Pulmonary Infection","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2011-03-02","conditions":"Atypical; Mycobacterium, Pulmonary, Tuberculous","enrollment":92},{"nctId":"NCT06846866","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability, and Drug Levels of BMS-986419 (Part 1) and the Effects Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2025-02-27","conditions":"Healthy Volunteers","enrollment":74},{"nctId":"NCT07214935","phase":"PHASE1","title":"A TQT Study of Effect of M2951 on Cardiac Repolarization","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2022-11-08","conditions":"Healthy","enrollment":36},{"nctId":"NCT07227779","phase":"PHASE2","title":"B-PaLMZ for TB Meningitis","status":"NOT_YET_RECRUITING","sponsor":"University of Minnesota","startDate":"2026-02-15","conditions":"Tuberculous Meningitis","enrollment":240},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT06411860","phase":"PHASE1","title":"A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants","status":"COMPLETED","sponsor":"Amgen","startDate":"2024-09-12","conditions":"Basic Science","enrollment":32},{"nctId":"NCT05807399","phase":"PHASE2","title":"PanACEA - STEP2C -01","status":"RECRUITING","sponsor":"Michael Hoelscher","startDate":"2023-04-14","conditions":"Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis","enrollment":390},{"nctId":"NCT06114628","phase":"PHASE2","title":"Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-01-09","conditions":"Pulmonary Tuberculosis","enrollment":2500},{"nctId":"NCT06746402","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2025-02-10","conditions":"Healthy Volunteers","enrollment":42},{"nctId":"NCT03244072","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery","status":"NOT_YET_RECRUITING","sponsor":"Jason Ahee, M.D.","startDate":"2026-06-01","conditions":"Endophthalmitis","enrollment":60000},{"nctId":"NCT07191834","phase":"","title":"A Study on the Short - Course Treatment Regimen Containing Pretomanid for Diabetes Mellitus Complicated With Rifampicin - Resistant/Multidrug - Resistant Pulmonary Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Pulmonary Hospital","startDate":"2025-09-30","conditions":"Rifampicin-resistant/Multidrug-resistant Pulmonary Tuberculosis, Type 2 Diabetes Mellitus (T2DM), Pretomanid","enrollment":60},{"nctId":"NCT06855264","phase":"PHASE1","title":"A Cardiac Liability Study of Varegacestat in Healthy Participants","status":"COMPLETED","sponsor":"Immunome, Inc.","startDate":"2025-02-24","conditions":"Healthy Volunteer","enrollment":32},{"nctId":"NCT04255277","phase":"PHASE1","title":"To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men.","status":"COMPLETED","sponsor":"Viatris Innovation GmbH","startDate":"2020-01-31","conditions":"Healthy Subjects","enrollment":97},{"nctId":"NCT02563327","phase":"PHASE3","title":"Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-05-30","conditions":"Tuberculosis","enrollment":53},{"nctId":"NCT05766267","phase":"PHASE2, PHASE3","title":"Short-course Regimens for the Treatment of Pulmonary Tuberculosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2023-11-21","conditions":"Tuberculosis, Pulmonary, Tuberculosis Infection","enrollment":288},{"nctId":"NCT05630274","phase":"PHASE1","title":"A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-04-16","conditions":"Healthy","enrollment":32},{"nctId":"NCT06649942","phase":"PHASE1","title":"A Study to Evaluate the Effects of KP-001 on the QT/QTc Intervals in Healthy Adults","status":"COMPLETED","sponsor":"Kaken Pharmaceutical","startDate":"2024-10-01","conditions":"Healthy Volunteers - Male and Female","enrollment":40},{"nctId":"NCT04550832","phase":"PHASE2","title":"PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)","status":"COMPLETED","sponsor":"LigaChem Biosciences, Inc.","startDate":"2021-10-28","conditions":"Infections and Infestations, Pulmonary Tuberculosis","enrollment":76},{"nctId":"NCT07162116","phase":"PHASE1","title":"A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants","status":"RECRUITING","sponsor":"Shijiazhuang Yiling Pharmaceutical Co. Ltd","startDate":"2025-07-06","conditions":"Acute Myeloid Leukemia With FLT3/ITD Mutation","enrollment":45},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT06186271","phase":"","title":"International Active Surveillance Study: Safety of Estrogen Estetrol (E4) Contraceptive Study (INAS-SEECS)","status":"RECRUITING","sponsor":"Center for Epidemiology and Health Research, Germany","startDate":"2025-04-24","conditions":"Contraception","enrollment":68100},{"nctId":"NCT07129629","phase":"PHASE2","title":"Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2025-08-20","conditions":"Tuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis","enrollment":45},{"nctId":"NCT07126639","phase":"NA","title":"A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Pulmonary Hospital","startDate":"2025-09-01","conditions":"Efficacy and Safety","enrollment":200},{"nctId":"NCT04310930","phase":"PHASE2, PHASE3","title":"Finding the Optimal Regimen for Mycobacterium Abscessus Treatment","status":"RECRUITING","sponsor":"The University of Queensland","startDate":"2020-03-02","conditions":"Pulmonary Disease Due to Mycobacteria (Diagnosis)","enrollment":300},{"nctId":"NCT06601192","phase":"PHASE1","title":"A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults","status":"COMPLETED","sponsor":"Enanta Pharmaceuticals, Inc","startDate":"2024-07-15","conditions":"RSV Infection, QTc Interval","enrollment":72},{"nctId":"NCT06112938","phase":"","title":"Alternative Treatment Strategies for Stenotrophomonas Maltophilia Pneumonia","status":"COMPLETED","sponsor":"Methodist Health System","startDate":"2022-07-21","conditions":"Stenotrophomonas Maltophilia Infection","enrollment":110},{"nctId":"NCT06423898","phase":"PHASE4","title":"Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.","status":"RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2024-10-09","conditions":"Endocarditis, Infective","enrollment":284},{"nctId":"NCT06352541","phase":"PHASE1","title":"Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo.","status":"NOT_YET_RECRUITING","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2025-09-30","conditions":"Healthy","enrollment":28},{"nctId":"NCT05821478","phase":"PHASE3","title":"Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients","status":"RECRUITING","sponsor":"Institut Pasteur","startDate":"2025-05-22","conditions":"Hidradenitis Suppurativa","enrollment":92},{"nctId":"NCT01944774","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Malate Sodium Chloride","status":"COMPLETED","sponsor":"TaiGen Biotechnology Co., Ltd.","startDate":"2013-03","conditions":"Pneumonia","enrollment":207},{"nctId":"NCT05331664","phase":"PHASE4","title":"Dropless Pars Plana Vitrectomy Study","status":"RECRUITING","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2022-07-25","conditions":"Rhegmatogenous Retinal Detachment","enrollment":168},{"nctId":"NCT03479736","phase":"","title":"A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-20","conditions":"Retinal Detachment, Achilles Tendon, Aneurysm, Dissecting","enrollment":117911},{"nctId":"NCT06363292","phase":"PHASE1","title":"Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2024-01-30","conditions":"Ophthalmological Agent Toxicity, Bacterial Conjunctivitis","enrollment":37},{"nctId":"NCT07014735","phase":"NA","title":"Effect of Hyperglycaemia and Moxifloxacin on QTc Interval in T2DM","status":"RECRUITING","sponsor":"Richmond Pharmacology Limited","startDate":"2023-04-13","conditions":"Diabetes Type 2, Hyperglycaemia (Diabetic), QT Interval, Variation in","enrollment":24},{"nctId":"NCT06837155","phase":"PHASE1","title":"A QT/QTc Evaluation Study of TS-172 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Taisho Pharmaceutical Co., Ltd.","startDate":"2025-03-03","conditions":"Healthy Volunteers","enrollment":52},{"nctId":"NCT05927649","phase":"PHASE1","title":"A TQTc Study for Omaveloxolone","status":"COMPLETED","sponsor":"Biogen","startDate":"2023-07-11","conditions":"Health Adult Subjects","enrollment":30},{"nctId":"NCT06820307","phase":"PHASE1","title":"Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-02-25","conditions":"Pain","enrollment":50},{"nctId":"NCT01689116","phase":"PHASE1","title":"Multiple-Dose Study of Effect of Bardoxolone Methyl on QT/QTC Interval Volunteers","status":"COMPLETED","sponsor":"Biogen","startDate":"2012-08-31","conditions":"Healthy Volunteers","enrollment":179},{"nctId":"NCT06785090","phase":"PHASE4","title":"Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery","status":"COMPLETED","sponsor":"Inas Abd","startDate":"2023-05-01","conditions":"Cataract, Cystoid Macular Edema After Phacoemulsification","enrollment":87},{"nctId":"NCT05387759","phase":"PHASE1","title":"A Thorough QT Study of Aticaprant (JNJ-67953964) in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-05-30","conditions":"Healthy","enrollment":60},{"nctId":"NCT03494907","phase":"PHASE1","title":"A Study to Evaluate the Effects of Single-dose Seltorexant on Electrocardiogram Intervals in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-09","conditions":"Healthy","enrollment":52},{"nctId":"NCT06194032","phase":"PHASE1","title":"A Study to Investigate the Effect on QTcF of Baxdrostat Compared With Placebo, Using Moxifloxacin as a Positive Control, in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-02-29","conditions":"Healthy Participants","enrollment":28},{"nctId":"NCT05893862","phase":"PHASE1","title":"A Study To Evaluate The Effect Of A Supratherapeutic Dose Of MK-8189 On The QTc Interval In Participants With Schizophrenia (MK-8189-019)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-06-26","conditions":"Schizophrenia","enrollment":107},{"nctId":"NCT02283788","phase":"PHASE1","title":"Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2007-03","conditions":"Epilepsy","enrollment":67},{"nctId":"NCT04779242","phase":"PHASE3","title":"Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia","status":"COMPLETED","sponsor":"Paratek Pharmaceuticals Inc","startDate":"2021-02-25","conditions":"Community-acquired Pneumonia, Bacterial Pneumonia","enrollment":670},{"nctId":"NCT06917495","phase":"PHASE2","title":"Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Shandong University","startDate":"2025-04-05","conditions":"Mild Spinal Tuberculosis","enrollment":300},{"nctId":"NCT05081401","phase":"PHASE3","title":"Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2022-05-23","conditions":"Multidrug Resistant Tuberculosis, Rifampicin Resistant Tuberculosis, Pre-XDR-TB","enrollment":1050},{"nctId":"NCT06081361","phase":"PHASE3","title":"Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Chest Hospital","startDate":"2023-12-22","conditions":"Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis","enrollment":186},{"nctId":"NCT04225078","phase":"PHASE1","title":"A Study to Evaluate the Effects of Loperamide (JNJ-289679) on Electrocardiogram Intervals in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-01-17","conditions":"Healthy Participants","enrollment":66},{"nctId":"NCT04175808","phase":"PHASE1","title":"Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults","status":"COMPLETED","sponsor":"Cytokinetics","startDate":"2019-11-14","conditions":"QT Intervals Changes, QTc Intervals Changes","enrollment":70},{"nctId":"NCT04750655","phase":"PHASE4","title":"Antibiotic Resistance In Eye Surgeries","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2021-03-01","conditions":"Antibiotic Resistance, Ocular Surface Microbiome, Gut Resistome","enrollment":108},{"nctId":"NCT06574828","phase":"PHASE1","title":"A Study to Find Out How Multiple Doses of BIIB091 Affect the Electrical Activity of the Heart in Healthy Participants","status":"COMPLETED","sponsor":"Biogen","startDate":"2024-08-29","conditions":"Healthy Volunteer","enrollment":69},{"nctId":"NCT06030219","phase":"PHASE1","title":"Microbiome Effect of Omadacycline on Healthy Volunteers","status":"COMPLETED","sponsor":"University of Houston","startDate":"2020-10-12","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT05293171","phase":"PHASE1","title":"Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects","status":"COMPLETED","sponsor":"BioLineRx, Ltd.","startDate":"2021-06-11","conditions":"Healthy Subjects","enrollment":38},{"nctId":"NCT06163105","phase":"NA","title":"The Effect of Gland Expression on the Regeneration of Meibomian Gland","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2024-10-03","conditions":"Meibomian Gland Dysfunction","enrollment":64},{"nctId":"NCT06879301","phase":"EARLY_PHASE1","title":"Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema, Retinal Vein Occlusion and Myopic Choroidal Neovascularisation Patients","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2025-10-19","conditions":"Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularisation","enrollment":60},{"nctId":"NCT05671029","phase":"PHASE1","title":"Thorough QT/QTc of Pritelivir in Healthy Subjects","status":"COMPLETED","sponsor":"AiCuris Anti-infective Cures AG","startDate":"2022-12-04","conditions":"Healthy Subjects","enrollment":64},{"nctId":"NCT04873323","phase":"PHASE1","title":"A QT/QTc Evaluation Study of TS-142 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Taisho Pharmaceutical Co., Ltd.","startDate":"2021-06-07","conditions":"Healthy Subjects","enrollment":59},{"nctId":"NCT06215521","phase":"PHASE1","title":"A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-12-15","conditions":"Healthy","enrollment":31},{"nctId":"NCT02754765","phase":"PHASE3","title":"Evaluating Newly Approved Drugs for Multidrug-resistant TB","status":"COMPLETED","sponsor":"Médecins Sans Frontières, France","startDate":"2016-12","conditions":"Tuberculosis, Multidrug-Resistant, Infection, Bacterial, Pulmonary Tuberculoses","enrollment":754},{"nctId":"NCT06787885","phase":"NA","title":"Evaluation of Efficacy and Safety Parameters of Different Antibiotics Regimens for Management of Empyema","status":"RECRUITING","sponsor":"Fayoum University","startDate":"2024-05-01","conditions":"Empyema, Pleural","enrollment":90},{"nctId":"NCT02050802","phase":"PHASE1","title":"Study to Assess the Effect of Macitentan on the Electrocardiogram (ECG) in Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"Actelion","startDate":"2011-08","conditions":"Healthy","enrollment":64}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ABDOMINAL PAIN UPPER"},{"count":1,"reaction":"CARDIAC ARREST"},{"count":1,"reaction":"CENTRAL NERVOUS SYSTEM LESION"},{"count":1,"reaction":"CLOSTRIDIUM DIFFICILE INFECTION"},{"count":1,"reaction":"DISCOMFORT"},{"count":1,"reaction":"DIZZINESS"},{"count":1,"reaction":"DYSPNOEA"},{"count":1,"reaction":"DYSPNOEA EXERTIONAL"},{"count":1,"reaction":"HAEMOGLOBIN DECREASED"},{"count":1,"reaction":"HAEMORRHAGE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Avelox"],"phase":"marketed","status":"active","brandName":"Moxifloxacin (Avelox)","genericName":"Moxifloxacin (Avelox)","companyName":"Connect Biopharma Australia Pty Ltd","companyId":"connect-biopharma-australia-pty-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in bacteria. Used for Community-acquired bacterial pneumonia, Acute bacterial sinusitis, Acute bacterial exacerbation of chronic bronchitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}